Product
Dostarlimab-Placebo
1 clinical trial
3 indications
Indication
Ovarian CancerIndication
OvarianClinical trial
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-29